Related Experiment Video
Updated: May 13, 2025

Biochemical Titration of Glycogen In vitro
Published on: November 24, 2013
Galectin-3: a novel biomarker of glycogen storage disease type III
Lucille Rossiaud1,2,3,4,5, Quentin Miagoux1,2,3, Manon Benabides1,2,3
1Université Paris-Saclay, Université d'Evry, Inserm, IStem, UMR861, Corbeil-Essonnes, France.
Abstract:
Glycogen storage disease type III (GSDIII) is a rare genetic disorder leading to abnormal glycogen storage in the liver and skeletal muscle. In this study, we conducted a comparative gene expression analysis of several in vitro and in vivo models and identified galectin-3 as a potential biomarker of the disease. Interestingly, we also observed a significant decrease in galectin-3 expression in mice treated with an AAV gene therapy. Finally, galectin-3 expression was studied in muscle biopsies of GSDIII patients, confirming its increase in patient tissue. Beyond the identification of this novel biomarker, our study offers a new perspective for future therapeutic developments.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Proteoglycans
Oligosaccharide Assembly
Multiple sugar molecules that may or may...

